福元医药：联苯苄唑溶液获得药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., has received the Drug Registration Certificate for Lufenuron Solution from the National Medical Products Administration, allowing the production of this medication for treating skin fungal diseases, including tinea, candidiasis, and vitiligo [1] Group 1 - The approval for Lufenuron Solution was granted following the acceptance notification received on January 12, 2024, indicating a successful application process [1] - The acquisition of the Drug Registration Certificate is considered equivalent to passing the consistency evaluation as per national policy regulations [1] - According to data from Minet, the sales revenue for Lufenuron Solution in China's three major terminal markets is approximately 375 million yuan in 2024 [1]